{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-014849","form_type":"8-K","ticker":"MBIO","cik":"0001680048","company_name":"MUSTANG BIO, INC.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.835758+00:00","generated_at":"2026-06-11T11:34:04.415602+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Mustang Bio Q2 net loss $16.2M; completes uBriGene asset sale for $6M","bullets":["Cash and equivalents $16.1M at June 30, down from $76.7M at Dec 31, 2022, reflecting Runway loan repayment.","Net loss $16.2M ($2.00/share) vs $19.1M ($2.50/share) in Q2 2022.","Closed amended asset sale to uBriGene for $6M upfront; expects $28M annual cost reduction.","Lead CAR T MB-106 shows 83% response in WM cohort; 95% ORR in FL cohort.","First pivotal Phase 2 WM patient expected Q1 2024; additional multicenter data in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-014849","json":"https://secwatch.observer/filing/0001558370-23-014849.json","markdown":"https://secwatch.observer/filing/0001558370-23-014849.md","text":"https://secwatch.observer/filing/0001558370-23-014849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023014849/0001558370-23-014849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023014849/tmb-20230814x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:34:04.415602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b6516ae0cdb8b08128c42ef7f3bfb5c6136becf","claim":"MUSTANG BIO, INC. reported the second quarter ended June 30, 2023 results: net income Net loss attributable to common stockholders was $16.2 million, or $2.00 per share.","evidence_excerpt":"On August 14, 2023, Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023014849/0001558370-23-014849-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss attributable to common stockholders was $16.2 million, or $2.00 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}